Second primary malignancy in Burkitt's lymphoma

Figures & data

Table I. Second primary malignancies in patients with Burkitt's lymphoma.

	Total population; person's risk = 175, person years at risk = 9481.70
	Observed	Expected	O/E	p-Value	CI lower	CI upper	Absolute excess risk
All sites	86	42.55	2.02	< 0.05	1.62	2.5	45.82
All sites excluding non-melanoma skin	86	42.35	2.03	< 0.05	1.62	2.51	46.03
All solid tumors	64	37.49	1.71	< 0.05	1.31	2.18	27.96
Skin excluding basal and squamous	5	2.25	2.22	0.14	0.72	5.19	2.9
Head and neck	5	1.54	3.26	0.04	1.06	7.6	3.65
Pancreatico-hepatobiliary	6	2.17	2.76	0.04	1.01	6.01	4.03
Esophagus	2	0.5	4.01	0.18	0.49	14.49	1.58
Colorectum	7	4.17	1.68	0.24	0.67	3.46	2.98
Anus, anal canal and anorectum	3	0.14	21.18	< 0.05	4.37	61.9	3.01
Lung and bronchus	3	5.28	0.57	0.44	0.12	1.66	− 2.41
Breast	7	3.31	2.12	0.1	0.85	4.36	3.89
Corpus and uterus, NOS	1	0.66	1.52	0.96	0.04	8.45	0.36
Male genital system	7	9.93	0.7	0.44	0.28	1.45	− 3.09
Urinary system	6	3.74	1.6	0.34	0.59	3.49	2.38
Brain and other nervous system	1	0.64	1.57	0.98	0.04	8.73	0.38
Thyroid	4	0.76	5.27	0.02	1.44	13.5	3.42
Hodgkin lymphoma	2	0.3	6.68	0.07	0.81	24.12	1.79
Non-Hodgkin lymphoma	10	1.96	5.11	< 0.05	2.45	9.39	8.48
Acute lymphocytic leukemia	1	0.15	6.77	0.26	0.17	37.75	0.9
Chronic lymphocytic leukemia	0	0.47	0		0	7.79	− 0.5
Acute myeloid leukemia	8	0.35	22.59	< 0.05	9.75	44.52	8.06
Chronic myeloid leukemia	1	0.17	6.05	0.3	0.15	33.68	0.88
Kaposi sarcoma	7	0.11	61.77	< 0.05	24.84	127.27	7.26